Literature DB >> 8634619

Diagnosis and management of migraine.

P J Goadsby1, J Olesen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634619      PMCID: PMC2351074          DOI: 10.1136/bmj.312.7041.1279

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  16 in total

1.  Treatment of migraine attacks with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine.

Authors:  P J Goadsby; A S Zagami; G A Lambert
Journal:  Headache       Date:  1991-06       Impact factor: 5.887

3.  Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.

Authors:  R Hering; A Kuritzky
Journal:  Cephalalgia       Date:  1992-04       Impact factor: 6.292

4.  Oral sumatriptan in acute migraine.

Authors:  P J Goadsby; A S Zagami; G A Donnan; G Symington; M Anthony; P F Bladin; J W Lance
Journal:  Lancet       Date:  1991-09-28       Impact factor: 79.321

5.  Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.

Authors:  R Jensen; T Brinck; J Olesen
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

6.  Presentation of a new instrument: the diagnostic headache diary.

Authors:  M B Russell; B K Rasmussen; J Brennum; H K Iversen; R A Jensen; J Olesen
Journal:  Cephalalgia       Date:  1992-12       Impact factor: 6.292

7.  Drug abuse in migraine patients.

Authors:  M Langemark; J Olesen
Journal:  Pain       Date:  1984-05       Impact factor: 6.961

8.  The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

Authors:  P J Goadsby; L Edvinsson
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

Review 9.  SUMATRIPTAN: a receptor-targeted treatment for migraine.

Authors:  M A Moskowitz; F M Cutrer
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

10.  The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.

Authors:  P Tfelt-Hansen; P Henry; L J Mulder; R G Scheldewaert; J Schoenen; G Chazot
Journal:  Lancet       Date:  1995-10-07       Impact factor: 79.321

View more
  16 in total

1.  Migraine.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 2.  Prophylactic migraine therapy: emerging treatment options.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 3.  Almotriptan: a review of its use in migraine.

Authors:  Susan J Keam; Karen L Goa; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Diagnosis and management of migraine. Low dose aspirin may be used for prophylaxis.

Authors:  C Nelson-Piercy; M De Swiet
Journal:  BMJ       Date:  1996-09-14

5.  Diagnosis and management of migraine. Differential diagnosis may be different in patients presenting to an ophthalmologist.

Authors:  A D Brown; P M Dodson; J R Ainsworth
Journal:  BMJ       Date:  1996-09-14

6.  Diagnosis and management of migraine. Care needs to be taken with treatment.

Authors:  J Lock; D Gallagher
Journal:  BMJ       Date:  1996-09-14

Review 7.  Frovatriptan.

Authors:  S E Easthope; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Acute Treatment of Migraine Headache.

Authors:  Marcelo E. Bigal; Richard B. Lipton
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

Review 9.  Headache in primary care: how important is diagnosis to management?

Authors:  Norma O'Flynn; Leone Ridsdale
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

Review 10.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.